References
- De Leo V, Musacchio MC, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update. 2016;22(5):634–646.
- Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.
- Hubacher D, Spector H, Monteith C, et al. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017;216(2):101–109.
- Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6):1656–1662.e1-4.
- Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19(7):677–668.
- Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205–1213.
- Trussell J, Hassan F, Henry N, et al. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception. 2014;89(5):451–459.
- Nilsson CG, Luukkainen T, Diaz J, et al. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet. 1981;1(8220 Pt 1):577–580.
- Jensen JT, Nelson AL, Costales AC, et al. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception. 2008;77(1):22–29.
- Goldstuck ND. Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems . Expert Rev Med Devices. 2017;14(8):593–599.
- Serfaty D, Bénézech JP, Heckel S, et al. Consensus of best practice in intrauterine contraception in France. Eur J Contracept Reprod Health Care. 2019;24(4):305–313.
- World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
- Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012;27(12):3432–3439.
- Gohari P, Berkowitz RL, Hobbins JC. Prediction of intrauterine growth retardation by determination of total intrauterine volume. Am J Obstet Gynecol. 1977;127(3):255–260.
- Soules M, Sherman S, Parrot E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5):874–878.
- Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126–130.
- Pinzauti S, Lazzeri L, Tosti C, et al. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol. 2015;46(6):730–736.
- Shaaban OM, Ali MK, Sabra AM, et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception. 2015;92(4):301–307.
- Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.
- DeMaria AL, Rivera S, Ramos-Ortiz J, et al. It's just a very personal thing': contraceptive influences and decision making among women living in Italy. Eur J Contracept Reprod Health Care. 2019;24(3):198–205.
- Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care. 2010;15(sup2):S42–S53.
- Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14–21.
- Abraham M, Zhao Q, Peipert JF. Young age, nulliparity, and continuation of long-acting reversible contraceptive methods. Obstet Gynecol. 2015;126(4):823–829.
- Mestad R, Secura G, Allsworth JE, et al. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011;84(5):493–498.
- Romano ME, Braun-Courville DK. Assessing weight status in adolescent and young adult users of the etonogestrel contraceptive implant. J Pediatr Adolesc Gynecol. 2019;32(4):409–414.
- Dehlendorf C, Grumbach K, Schmittdiel JA, et al. Shared decision making in contraceptive counseling. Contraception. 2017;95(5):452–455.